I
n September 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) launched its 90 -90 -90 initiative: an ambitious treatment target to help end the AIDS epidemic by 2020. The 90 -90 -90 goal aims to diagnose 90% of HIV-infected persons worldwide, link 90% of these to antiretroviral therapy (ART), and achieve virologic suppression among 90% of ART recipients. Such coverage would produce virologic suppression in 73% (0.90 × 0.90 × 0.90) of patients worldwide, a marked increase from current estimates of 29% (1) . The 90 -90 -90 strategy addresses the "HIV treatment cascade," documenting attrition in the continuum of care leading from HIV diagnosis through linkage to care to virologic suppression while receiving ART and retention in care. Current South African estimates suggest that 67% of HIV-infected patients have undiagnosed disease or are unlinked to care, 33% receive ART, and only 24% have achieved virologic suppression (2) . egy with the UNAIDS target strategy. We projected the progress of cohorts through the continuum of care for 10 years, taking into account new infections, diagnoses, ART initiations, and ART-associated virologic outcomes. Over both 5-and 10-year horizons, we projected the following outcomes: cumulative HIV transmissions, deaths, years of life saved (YLS), numbers of children becoming orphans, lifetime costs (in 2014 U.S. dollars), and incremental cost-effectiveness. Outcomes are reported both undiscounted (for clinical and budget impact purposes) and discounted at 3% annually (for costeffectiveness evaluation).
Cohort Definitions
The current population of HIV-infected adults (aged ≥15 years) in South Africa (the "prevalent cohort") was assigned at model outset to stages in the care continuum: 67% with undiagnosed disease, unlinked to care, or otherwise not receiving ART; 9% with unsuppressed viral load and receiving ART; and 23% and 1% of the total HIV-infected population with suppressed viral load and receiving first-and second-line ART (2, 4) . Each year, we introduced an incident cohort and thereafter combined outcomes of the 2016 prevalent cohort and all later incident cohorts.
The CEPAC-I Model
The CEPAC-I model is a microsimulation of HIV disease progression and treatment in resource-limited settings (5) . It aggregates the experience of large numbers of individual patients to project the populationlevel effects of alternative treatment scale-up policies (6) . Individual patient characteristics (including age, sex, CD4 cell count, and HIV RNA level) are generated by random draws from distributions, some of which (for example, CD4) are dependent on the simulated patient's stage in the HIV continuum of care at model outset (not in care, receiving ART with suppressed viral load, or receiving ART without suppressed viral load) ( Tables 1 and 2 ).
The CEPAC-I model simulates the success and failure of disease detection, linkage to care, ART initiation, virologic suppression, and retention in care. It also simulates the risk for opportunistic infection, which increases with declining CD4 counts. Patients with undetected disease or those who are otherwise unlinked experience immunologic and CD4 cell count decline, and HIV is detected through testing or the development of an opportunistic infection. Only patients who achieve virologic suppression on ART experience CD4 cell count increases; patients with unsuppressed viral load who are receiving ART achieve no CD4 cell count recovery yet continue to face reduced risk for opportunistic infection related to CD4 cell counts while accruing ART costs (5, (7) (8) (9) .
For those patients initiating ART, the 48-week virologic suppression rate is 72% (2, 10) . Levels of HIV RNA are monitored according to South African guidelines (25) . Patients in whom ART failure is detected may be switched to a second-line regimen, if one is available. Patients in care are at adherence-dependent risk for loss to follow-up at monthly rates ranging from 0.2% to 1.1%, resulting in an 80% probability of remaining in care at 5 years (12) (13) (14) .
Additional model details, including model figures, flow charts, state-space definitions, user guides, data fields, protocols for data assembly, and stopping rules, can be found at www.massgeneral.org/mpec/cepac/.
Transmissions
To estimate HIV transmission, we used the model's unique capacity to report monthly patient-level information on HIV RNA. We assumed that HIV viral load drives the rate at which infected individuals transmit HIV to others. We linked published estimates of viral load-specific transmission (15, 16) to monthly CEPAC-I output on each patient's viral load ( Table 1) . This method (and the published data it is based on) does not consider age, sex, or risk group, but instead uses aggregated transmission events stratified by viral load. In the model, patient viral load depends on the baseline HIV RNA value (17) and whether the patient is acutely infected (26) , is virologically suppressed, is either becoming suppressed or experiencing rebound, or is at an advanced stage of disease (CD4 cell count ≤0.200 × 10 9 cells/L). During the 6-month period of acute infection, we amplified transmissions 7.25-fold (16) . The cumulative viral load estimated by the model across all patients and all 12 months was used to estimate the yearly number of incident infections over a 10-year horizon.
Clinical Outcomes
For each of the yearly cohorts, the CEPAC-I model provides the monthly distribution of all living patientsincluding those newly infected-across the various stages of the cascade. The output also provides, for 
Maternal Orphans
We considered the children of HIV-infected women in 2016 (current children) and children projected to be born to HIV-infected women over the next 10 years (new children). We defined "maternal orphans" as children younger than 18 years whose mother died of HIV/ AIDS (27) . We also report results for particularly vulnerable orphans younger than 5 years. Numbers of orphans and their ages were estimated by using country-and age-specific fertility rates, derived from the United Nations and Statistics South Africa and corrected for the prevalence of HIV among women by age (11, 18, 28) . We adjusted our estimate to take into account reductions in fertility due to HIV infection (19); the risk for child mortality, both before and after becoming orphaned (29) ; and the possibility that an orphan will reach the age of 18 years (and thus no longer meet the definition of orphanhood) at some point in the 10-year time horizon. We tallied both cumulative orphans (all children orphaned between 2016 and 2026) and current orphans (living orphans aged <18 years at a given time).
Costs
Costs of first-and second-line ART are $137 and $375 per year, respectively (20) . Costs of HIV-related care include treatment of opportunistic infection, laboratory monitoring, and CD4-stratified routine care (Tables 1 and 2) (22, 23) . When necessary, year-specific gross domestic product deflators were used to first update all South African costs to 2014 rand and were subsequently converted to 2014 U.S. dollars (21, 30, 31). times that of the highest viral load stratum (>100 000 copies/mL). † Using age-specific HIV prevalence and age-specific fertility rate risk ratios between HIV-infected and uninfected, we derived HIV-and agespecific fertility rates. These rates per 100 PYs translate into a fertility rate of 2.0 for HIV-infected persons and 2.7 for non-HIV-infected persons (11, 18, 19) . ‡ Adherence and retention intervention affects ART efficacy (% suppressed) and attenuates loss to follow-up, as described in the Methods section.
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Strategies
The current pace strategy reflects current HIV detection, treatment, and retention efforts in South Africa, resulting in gradual increases in overall virologic suppression from 24% to 36% over the next 5 years and 44% over the next 10 years (Tables 1 and 2) .
For the UNAIDS target strategy, we adjusted parameters in the CEPAC-I model to achieve the objectives of the 90 -90 -90 initiative in South Africa. Model output demonstrates that both testing every 2 years on average and linking 50% of identified cases are required to achieve 90% diagnosis and 90% on ART in 5 years. Average CD4 cell count at ART initiation among persons in the previously undetected prevalent and incident cohorts increases to 0.305 and 0.364 × 10 To achieve overall virologic suppression of 73%, we assumed the routine implementation of a highly effective, monthly adherence and retention intervention. Such a program might require intensive, door-to-door services costing as much as $13 per person receiving ART per month-a figure reported by a study of a comparably exhaustive, community-based intervention (24) . Although no reports of an intervention of this scope and efficacy are currently available, we assume here that this intervention could increase both the 48-week suppressive efficacy of ART from 72% (under the current pace strategy) to 87% and the 5-year probability of retention in care from 80% to 88%.
The UNAIDS target strategy adds substantial costs for case detection. The costs of extensive outreach were assumed to be $20 per positive test result and $7 per negative test result (24) . The number of persons tested each year was estimated by dividing the number of persons linked to treatment by the proportion of the population older than 15 years with undiagnosed HIV. As undiagnosed prevalence decreases from 8% to~2% over 10 years, an increased number of negative test results is required to find each unlinked HIV-infected person.
Statistical Analysis
To examine the robustness of our findings in the face of changes in the underlying data, we conducted numerous one-way and multiway sensitivity analyses, varying input parameters across a broad range of plausible alternative values. The variables of interest were the duration of acute infection (base value, 6 months; plausible range, 3 to 12 months), the efficiency of testing and linkage to care (base linkage rate, 50%; plausible range, 25% to 90%), annual ART costs (base values, $137 and $375 for first-and second-line treatment, respectively; plausible ranges, 50% to 100% of base values), and the cost of adherence and retention interventions (base value, $155; plausible range, 50% to 200% of base value). We also considered alternative pathways leading to the UNAIDS virologic suppression target.
Role of the Funding Source
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RESULTS

Cascade of Care
Our model predictions of the proportion of the population in each cascade stage at the end of year 1 under the current pace strategy were calibrated to published estimates and are within an absolute 3% at each stage ( Figure 1) (2) . The current pace strategy results in gradually improved cascade outcomes; by year 10, 44% of living HIV-infected persons have achieved virologic suppression (Figure 1) . The UNAIDS target strategy achieves 81% diagnosis and 74% virologic suppression by year 5; by year 10, the suppression rate among living HIV-infected persons is 80% (Figure 1) .
Taking into account incident cases and deaths over the next decade, we project under the current pace strategy that 2.632 million South Africans will achieve virologic suppression while receiving ART and that 2.963 million will have undiagnosed disease or remain unlinked to care (Figure 2) . Under the UNAIDS target strategy, we project that more than 2 million fewer persons (or 870 000) will have undiagnosed disease or remain unlinked to care and almost 2.5 million more (or 5.070 million) will be receiving ART and achieve virologic suppression (Figure 2) .
HIV Transmissions
Under the current pace strategy, we project 450 000 HIV transmissions in year 1 (32), yielding an annual incidence of 1.80%. We validated this modeldriven incidence by comparing it with the annual incidence among persons 15 to 49 years of age, which the 2012 South Africa HIV national survey reports as 1.72% (11) . Over 10 years, we project 4.413 million new infections ( Table 3 and Appendix Figure 1 , available at www .annals.org). Under the UNAIDS target strategy, 2.362 million new infections are projected over 10 years (Table 3), suggesting that 2.051 million transmissions will be averted (Appendix Figure 1) .
Deaths and Life-Years Saved
Over the next 10 years and inclusive of each year's newly transmitted cases, the current pace and the UN-AIDS target strategies will result in 4.985 million and 2.507 million cumulative deaths, respectively, among HIV-infected persons. Compared with the current pace strategy, the UNAIDS target strategy will result in 3.002 million additional YLS over 5 years and 13.340 million additional YLS over 10 years ( Table 3) .
Maternal Orphans
In 2013, there were an estimated 900 000 living maternal orphans owing to HIV/AIDS in South Africa (27, 33 ). Under the current pace strategy, 2.979 million
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Africa more children will be orphaned owing to HIV infection within 10 years; in 2026, after accounting for orphan mortality and "aging out," we project that there will be 2.443 million living maternal orphans. In contrast, if the UNAIDS target strategy is reached, we project that there will be a cumulative 1.290 million children orphaned, and 1.185 million living orphans in 10 years-a cumulative difference of 1.689 million orphans ( Table 3 and Figure 3 ).
Costs and Cost-Effectiveness
Model output demonstrates an average annual cost of $930 for patients in care and receiving ART, consistent with annual patient costs previously reported in South Africa (34) . Total 5-and 10-year costs for the current pace strategy are $18.674 billion and $38.353 billion, respectively, of which $1.986 billion (11%) and $4.415 billion (12%) are ART costs ( Table 3) . Total 5-and 10-year costs for the UNAIDS target strategy are $26.639 billion and $54.332 billion, respectively, of which $3.409 billion (13%) and $8.032 billion (15%) are ART costs, $1.182 billion (4%) and $2.045 billion (4%) are testing costs, and $3.604 billion (14%) and $7.858 billion (14%) are adherence and retention intervention costs.
The incremental cost-effectiveness ratio of the UNAIDS target compared with the current pace strategy (change in costs divided by change in YLS) is $2720 per YLS over 5 years and $1260 per YLS over 10 years. These incremental cost-effectiveness ratios represent 42% and 19%, respectively, of the South African per capita gross domestic product ($6500) (30), suggesting that the UNAIDS target strategy is very costeffective by international standards in this setting (35) .
Sensitivity Analyses
Changing the duration of acute HIV infection from 6 months to 12 months results in larger incremental benefits from the UNAIDS target strategy in terms of cumulative deaths, YLS, and orphans averted; in contrast, changing the duration of acute HIV infection from 6 months to 3 months results in smaller incremental benefits in terms of these outcomes. Most variations in these sensitivity analyses remain less than 20% from the base-case values (Appendix Table 1 , available at www .annals.org). With lower testing and linkage rates but increased ART adherence and retention in the UNAIDS target strategy, we achieve 72% virologic suppression at year 5 via an alternative pathway (Appendix Figure 2 , available at www.annals.org). This alternative UNAIDS target strategy nearly reaches the 73% suppression end point but fails to meet the interim targets of 90% of cases diagnosed and 90% of patients receiving ART, resulting in less favorable UNAIDS target outcomes owing to the decreased proportion of persons receiving ART and HIV care (Appendix Table 1 ).
When the testing and linkage efficiency was halved (only 25% of HIV-infected patients linked to care each time they test positive) and the per-person adherence and retention cost was doubled, the UNAIDS target strategy remains both very expensive at 5 and 10 years ($31.445 billion and $64.370 billion, respectively) but also very cost-effective ($4330 per YLS and $2040 per YLS, respectively). Conversely, if testing and linkage efficiency reach 90% and adherence and retention intervention and ART costs were both halved, the 5-and 10-year costs of the UNAIDS target strategy would be $21.487 billion and $42.726 billion, respectively, and the strategy would be substantially more cost-effective ($1490 per YLS and $600 per YLS, respectively) (Appendix Table 2 , available at www.annals.org).
DISCUSSION
UNAIDS is right to label the 90 -90 -90 initiative "a momentous opportunity" to "end the AIDS epidemic" (1). We considered a wide range of clinical, epidemiologic, and social performance standards by which policymakers and donors might measure return on investment. By every one of these measures, achieving the UNAIDS target strategy could have a transformative impact: averting millions of new HIV infections, saving millions of lives and tens of millions of years of life, and preventing millions of children from becoming orphans-and thereby curtailing the global pandemic.
Although this initiative will not be easy, we find that it will be highly cost-effective and well worth trying. Our analysis suggests that the 90 -90 -90 performance targets can be attained only if every step in the continuum leading from HIV detection to durable viral suppression can be made to function sustainably at "best practice" levels. For example, we found that 90% rates of diagnosis and linkage will require aggressive HIV screening, probably as often as once every 2 years, across the South African population. Furthermore, achieving 73% overall virologic suppression will require individual 48-week ART suppression rates of~87%, accompanied by 5-year retention rates of nearly 90%. These perfor- The difference in the height of the bars in each year indicates the cumulative number of additional transmissions in the current pace strategy compared with the UNAIDS target strategy. ART = antiretroviral therapy; UNAIDS = Joint United Nations Programme on HIV/AIDS.
ORIGINAL RESEARCH Anticipated Clinical and Economic Effects of 90 -90 -90 in South Africa
mance levels are as good as those reported in the most rigorous U.S.-based and international clinical trials, which generally bias enrollment to the most adherent patients (36) . We emphasize that these performance targets are ambitious but plausible: Emerging evidence suggests that best practices can be implemented and sustained, both in resource-rich and resource-constrained settings. For example, very high virologic suppression rates at the population level have already been reported from Australia (62%), United Kingdom (58%), and the higher-burdened Botswana (70%) (37, 38) .
The initiative will also not be cheap. We estimate a cost in South Africa of $54 billion over the next 10 years-an increase of $16 billion over current HIV detection and treatment efforts. To put this in perspective, the 2014 -2015 South Africa National Strategic Plan proposed that $2.8 billion would be needed in 2014 -2015 for combined efforts in prevention and treatment of HIV, tuberculosis, and sexually transmitted infections (39) . This would require a 14% annual budget increase over 10 years ($54 billion total) for the investment to be met. However, our analysis also highlights that such investments would yield extraordinary returns. Scale-up would be as cost-effective as ART itself (5, 22, 40, 41) and may be even more cost-effective in settings with higher HIV prevalence, especially among young persons. This compelling cost-effectiveness case holds even though our analysis excluded both the social and economic value of keeping mothers alive and the productivity costs saved by curbing the HIV epidemic over time. In short, we found that although reaching the UNAIDS target strategy exceeds current budgetary allocations, it would be a very cost-effective proposition.
Like any model-based exploration of a yet-to-beimplemented intervention, our analysis is limited by uncertainties in the input data and by some inevitable simplifications in our portrayal of the system. Key uncertainties and limitations include omission of alternative plausible pathways that might lead to 73% virologic suppression, use of a single criterion to characterize phenomena that may vary by sex (for example, differences in rates of testing or transmission), exclusion of orphans' outcomes in the calculation of deaths and In addition, we highlight that this analysis is specific to both the South African setting and time in the epidemic. Although we have made every effort to report these uncertainties transparently and to bias the analysis whenever possible against the cost-effectiveness conclusions, our findings (±20%) are robust in the face of many uncertainties.
We found that if the 90 -90 -90 targets for diagnosis of HIV, receipt of ART, and virologic suppression can each be achieved in South Africa, enormous population and clinical benefits would follow. Broad variation in our key input parameters across their plausible ranges produced relatively small swings in overall outcomes and did little to undermine the overall conclusion that the 90 -90 -90 strategy can work; that it offers decision makers and donors a superb return on investment; and that there is nothing overstated about the UNAIDS suggestion that it could "lay the foundation for a healthier, more just and equitable world for future generations" (1) . Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Walensky had access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. For the current pace strategy, the literature-derived data and the model-projected effects on the current South African cascade after 1, 5, and 10 y are shown. At 10 y of the current pace strategy, 44% of living patients have virologic suppression. For the UNAIDS target strategy, model output demonstrates results that might be achieved in 5 and 10 y, compared with the 90 -90 -90 benchmark. In the alternative UNAIDS target strategy, lower testing and linkage rates and higher rates of virologic suppression than in the UNAIDS target strategy base case were used to achieve viral suppression goals, but less than 81% of persons on ART. Although the UNAIDS target strategy and the alternative UNAIDS target strategy have similar viral suppression rates (approximately 73% at 5 y), they differ in the proportion of persons receiving ART (81% and 75%, respectively). The number of patients alive in the 3 strategies over time differs owing to an increased number of transmissions and deaths. ART = antiretroviral therapy; UNAIDS = Joint United Nations Programme on HIV/AIDS.
